https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/rejoin-pcr-colorants Slide 1: Home printer OEM

https://www.avient.com/products/polymer-additives/repellant-antimicrobial-additives/cesa-withstand-antimicrobial-additives Slide 1: Injection molder

https://pt.avient.com/products/polymer-colorants/liquid-color-concentrates/hiformer-liquid-masterbatches Slide 1: Fabricante de embalagens farmacêuticas

https://www.avient.com/products/long-fiber-technology/long-fiber-technologies/onforce-long-glass-fiber-reinforced-polypropylene-composites Slide 1: Heavy Truck manufacturer

https://www.avient.com/products/polymer-additives/foaming-agents/hydrocerol-chemical-foaming-agents Slide 1: siding & cladding Manufacturer

https://www.avient.com/products/long-fiber-technology/complet-long-carbon-fiber Slide 1: prosthetics and orthotics BRAND

https://www.avient.com/products/thermoplastic-elastomers/versaflex-hc-thermoplastic-elastomers Slide 1: MEDICAL Device manufacturer

LEARN MORE https://www.avient.com/products/long-fiber-technology/long-fiber-technologies/compl-t-long-fiber-reinforced-structural-thermoplastics Slide 1: Industrial fan manufacturer

https://www.avient.com/products/polymer-additives/surface-modifier-additives/cesa-anti-block-additives Slide 1: Flexible packaging manufacturer

Pro Forma Financial Information The Company acquired Avient Protective Materials (“Dyneema”) on September 1, 2022 (the “Acquisition Date”) and sold the Distribution segment on November 1, 2022. To provide comparable results, the company references “pro forma” financial metrics, which include the business results of Avient Protective Materials for periods prior to the Acquisition Date, as if the transaction occurred on January 1, 2021 and reflect Distribution as a discontinued operation. GUIDANCE $800 $754 Guidance Actual $128 $123 Guidance Actual Sales Adjusted EBITDA (in millions) $0.56 $0.57 Guidance Actual Adjusted EPS (in millions) 9 • Demand impacted by destocking and cautious customer sentiment • Positive net price benefit: o CAI - Pricing flat and raw material deflation o SEM - Pricing flat with unfavorable mix related to healthcare, more than offset with raw material deflation • Cost reductions driven by Clariant synergies and reduced administrative costs Q3 EBITDA BRIDGE ($ millions) CAI: Price / Mix -) Deflation 22) SEM: Price / Mix (6) Deflation 13) Net Price Benefit 29) Cost Reductions 13) Wage Inflation (8) FX 1) Q3 2023 Actual $ 123) Adjusted EBITDA Q3 2022 Pro Forma $ 137) Demand (49) 10 2 0 2 3 G U I D A N C E Q4 2023 GUIDANCE VS.